Livagen 20mg | Hepatic Bioregulator Peptide

Description

Livagen 20mg – Synthetic Tetrapeptide for Hepatic Tissue Research

Livagen (Ala-Glu-Asp-Gly, AEDG) is a synthetic tetrapeptide developed through the pioneering research of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology . It is structurally related to Cartalax (AED) and belongs to the same family of short peptide bioregulators that have been the subject of extensive Russian research on tissue-specific regulation and cellular aging .

Livagen has been investigated for its ability to modulate nucleolar organizer regions and increase the number of nucleoli per cell . In vitro studies have demonstrated that Livagen can induce alterations in the C segments of chromosomes 1 and 9 in donor cells, suggesting effects on chromatin structure and gene expression .

Key Research Applications

• Hepatic Tissue and Liver Function Research – Investigated for its potential role in supporting hepatocyte function, regeneration, and metabolic regulation in liver tissue models.

• Nucleolar Organizer Region Studies – Shown to increase the number of nucleolar organizer regions (NORs) and nucleoli per cell, suggesting a role in ribosomal RNA synthesis and cellular protein production .

• Chromatin and Gene Expression Research – Studies have shown that Livagen can induce alterations in chromosomal structure, specifically in the C segments of chromosomes 1 and 9, indicating potential effects on gene regulation .

• Cellular Senescence and Aging Research – Related short peptides (AEDG) have demonstrated the ability to prevent cellular senescence in human periodontal ligament stem cells, as detected by p16 and p21 markers . This suggests potential applications in aging and cellular health research.

• Neuroprotective and Neuronal Differentiation Research – The AEDG peptide has shown positive effects on neurogenic differentiation gene expression and protein synthesis in human mesenchymal stem cells . This cross-tissue application highlights the peptide’s versatility in research models.

Molecular and Technical Specifications

• Molecular Formula: C₁₈H₃₁N₅O₉

• Molecular Weight: ~461.47 g/mol 

• Purity: ≥98% (HPLC)

• Dosage: 20mg per vial

• Form: Lyophilized powder

• Sequence: H-Ala-Glu-Asp-Gly-OH (AEDG)

• Synonyms: Livagen; Ala-Glu-Asp-Gly; AEDG; T-31

• CAS Number: 433257-50-2 

• Storage: -20°C; protect from light 

Research Background

Livagen was developed as part of a broader program investigating the biological effects of short peptides on cellular function and aging. Peptide bioregulators like Livagen have been shown to regulate gene expression and protein synthesis, stimulate cell proliferation and differentiation, and decrease apoptosis .

In a study of peptide effects on neuronal differentiation, the AEDG peptide positively influenced neurogenic differentiation gene expression and protein synthesis in human gingival mesenchymal stem cells . Peptides AEDG and KED prevented cellular senescence in human periodontal ligament stem cells during long-term cell cultivation, as detected by p16 and p21 markers . These findings suggest that Livagen may have broader applications in regenerative research beyond liver tissue.

Reconstitution Guidelines

Reconstitute the lyophilized peptide with sterile water or bacteriostatic water. Gently swirl (do not vortex) to aid dissolution. Once reconstituted, aliquot into smaller volumes and store at -80°C for long-term stability to minimize freeze-thaw cycles.

Important Safety Notice

⚠️ FOR RESEARCH PURPOSES ONLY

This product is strictly intended for in-vitro research and laboratory use only. It is not approved for human consumption, therapeutic use, or clinical applications by any regulatory authority (e.g., FDA, EMA, MHRA) . Livagen is not registered as a medicinal product in the UK, EU, or US. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

This product is sold as a research chemical only. Not for human or veterinary therapeutic use.

Cartalax 20mg | Chondroprotective Bioregulator Peptide